BRPI0616572A2 - tratamento de distúrbios neurodegenerativos - Google Patents

tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0616572A2
BRPI0616572A2 BRPI0616572-9A BRPI0616572A BRPI0616572A2 BR PI0616572 A2 BRPI0616572 A2 BR PI0616572A2 BR PI0616572 A BRPI0616572 A BR PI0616572A BR PI0616572 A2 BRPI0616572 A2 BR PI0616572A2
Authority
BR
Brazil
Prior art keywords
neurodegenerative disorders
erythropoietin
treatment
medicament
glycosylation
Prior art date
Application number
BRPI0616572-9A
Other languages
English (en)
Inventor
Anton Haselbeck
Frank Herting
Joerg Huwyler
Michael Jarsch
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37622051&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0616572(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0616572A2 publication Critical patent/BRPI0616572A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS. A presente invenção refere-se ao uso de uma molécula entropoiética para a produção de um medicamento para o tratamento de distúrbios neurodegenerativos do cérebro e da medula espinha, pela administração de uma quantidade efetiva do medicamento na corrente sangúínea de um paciente em necessidade desse tipo de terapia, em que a molécula eritropoiética compreende uma porção eritropoietina, contando com, pelo menos, um grupo amino livre, selecionado do grupo composto por eritropoietina humana e por análogos da mesma com a seqúência da eritropoietina humana modificada pelo acréscimo de 1 a 6 sítios de glicosilação ou um rearranjo de, pelo menos, um sítio de glicosilação, o referido eritropoietina sendo co- valente ligado a "n" grupos pol i(etilenoglicol) da fórmula -CO-(CH~ 2~)~ x~- (OCH~ 2~CH~ 2~)~ m~-OR e um kit compreendendo um molécula eritropoiética de acordo com a invenção.
BRPI0616572-9A 2005-09-28 2006-09-18 tratamento de distúrbios neurodegenerativos BRPI0616572A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05108946 2005-09-28
PCT/EP2006/066438 WO2007039436A1 (en) 2005-09-28 2006-09-18 Treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0616572A2 true BRPI0616572A2 (pt) 2009-11-24

Family

ID=37622051

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0616572-9A BRPI0616572A2 (pt) 2005-09-28 2006-09-18 tratamento de distúrbios neurodegenerativos

Country Status (18)

Country Link
US (2) US20070072795A1 (pt)
EP (1) EP1940447B1 (pt)
JP (1) JP5096345B2 (pt)
KR (1) KR20080038440A (pt)
CN (1) CN101277715B (pt)
AR (1) AR055654A1 (pt)
AU (1) AU2006298826B2 (pt)
BR (1) BRPI0616572A2 (pt)
CA (1) CA2622609A1 (pt)
DK (1) DK1940447T3 (pt)
ES (1) ES2445035T3 (pt)
IL (1) IL189853A (pt)
PL (1) PL1940447T3 (pt)
RU (1) RU2467761C2 (pt)
SI (1) SI1940447T1 (pt)
TW (1) TWI380824B (pt)
WO (1) WO2007039436A1 (pt)
ZA (1) ZA200802270B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
CL2008002054A1 (es) 2007-07-17 2009-05-29 Hoffmann La Roche Metodo para la regeneracion de una columna de cromatografia de intercambio cationico despues de la elusion de eritropoyetina monopeguilada y metodo para obtener una eritropoyetina monopeguilada, incorporando el metodo de regeneracion de la columna de intercambio cationico.
RU2515914C1 (ru) * 2013-02-12 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика" Гибридный белок на основе рекомбинантного эритропоэтина человека, обладающий пролонгированным действием (варианты), и способ его получения
RU2561050C2 (ru) * 2013-08-28 2015-08-20 Федеральное государственное бюджетное учреждение науки Институт биофизики клетки Российской академии наук (ИБК РАН) Применение белка yb-1 и его фрагментов для изготовления лекарственных средств при лечении болезни альцгеймера
AR113091A1 (es) * 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644077A (en) * 1898-08-01 1900-02-27 Farbenfabriken Of Elberfeld Company Acetyl salicylic acid.
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5968502A (en) * 1991-11-05 1999-10-19 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US6703381B1 (en) * 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
CA2383940A1 (en) * 1999-04-13 2000-10-19 The Kenneth S. Warren Laboratories, Inc. Modulation of excitable tissue function by peripherally administered erythropoietin
US6225895B1 (en) * 1999-05-26 2001-05-01 Floyd E. Bigelow, Jr. Towed vehicle monitor system
CZ299516B6 (cs) * 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
JP3967594B2 (ja) * 2000-05-15 2007-08-29 エフ．ホフマン−ラ ロシュ アーゲー 新しい薬剤組成物
JP2004502706A (ja) * 2000-07-10 2004-01-29 アルバート・ティー・ナイトー 血液脳関門を開口する方法
DE10043457A1 (de) * 2000-09-04 2002-03-28 Hannelore Ehrenreich Verfahren zur Behandlung von Schizophrenie und verwandten Psychosen sowie Verwendung von Erythropoietin oder Erythropoietinderivaten zur Behandlung von Schizophrenien und verwandten Psychosen
DE60144439D1 (de) * 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
US6531121B2 (en) * 2000-12-29 2003-03-11 The Kenneth S. Warren Institute, Inc. Protection and enhancement of erythropoietin-responsive cells, tissues and organs
US7767643B2 (en) * 2000-12-29 2010-08-03 The Kenneth S. Warren Institute, Inc. Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
CA2488497A1 (en) * 2002-06-11 2003-12-18 The Burnham Institute Neuroprotective synergy of erythropoietin and insulin-like growth factor
US20040122216A1 (en) * 2002-07-01 2004-06-24 Jacob Nielsen Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs
US7459436B2 (en) * 2002-11-22 2008-12-02 Hoffmann-La Roche Inc. Treatment of disturbances of iron distribution
US7718363B2 (en) * 2003-04-25 2010-05-18 The Kenneth S. Warren Institute, Inc. Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds
MXPA05012515A (es) * 2003-05-19 2006-05-25 Kenneth S Warren Inst Inc Citocinas protectoras de tejido para la proteccion, restablecimiento y potenciacion de celulas, tejidos y organos sensibles, con una ventana terapeutica ampliada.
JP2007514673A (ja) * 2003-12-19 2007-06-07 エフ．ホフマン−ラ　ロシュ　アーゲー 慢性炎症性腸疾患の際の鉄分布障害の処置におけるエリスロポエチンの使用
ATE488519T1 (de) * 2005-09-28 2010-12-15 Hoffmann La Roche Indol-3-ylcarbonylazaspiroderivate als vasopressinrezeptorantagonisten

Also Published As

Publication number Publication date
CA2622609A1 (en) 2007-04-12
CN101277715B (zh) 2013-03-27
AR055654A1 (es) 2007-08-29
DK1940447T3 (da) 2014-01-20
AU2006298826A1 (en) 2007-04-12
ES2445035T3 (es) 2014-02-27
EP1940447A1 (en) 2008-07-09
AU2006298826B2 (en) 2010-04-01
TWI380824B (zh) 2013-01-01
US20100267632A1 (en) 2010-10-21
SI1940447T1 (sl) 2014-03-31
WO2007039436A1 (en) 2007-04-12
IL189853A0 (en) 2008-11-03
PL1940447T3 (pl) 2014-04-30
KR20080038440A (ko) 2008-05-06
JP5096345B2 (ja) 2012-12-12
CN101277715A (zh) 2008-10-01
JP2009510008A (ja) 2009-03-12
ZA200802270B (en) 2009-02-25
US20070072795A1 (en) 2007-03-29
RU2008116309A (ru) 2009-11-10
EP1940447B1 (en) 2013-11-27
IL189853A (en) 2012-06-28
RU2467761C2 (ru) 2012-11-27
TW200727911A (en) 2007-08-01

Similar Documents

Publication Publication Date Title
BR112022002599A2 (pt) Vesícula extracelular ligada a moléculas e usos da mesma
BR0116381A (pt) Conjugado, composição farmacêutica que compreende o mesmo e sua utilização, processo para o tratamento profilático e/ou terapêutico de distúrbios, processo para a preparação de um conjugado, compostos e glicoproteìnas de eritropoetina
CN1930190B (zh) 透明质酸衍生物及含有其的药剂
ES2545525T3 (es) Polímeros biocompatibles, composiciones que los contienen y su uso para la preparación de medicamentos
BR0002276A (pt) Conjugado, composição que compreendeconjugados, composição farmacêutica, utilizaçãode um conjugado ou composição e processso paraa preparação de compostos
BR112022003628A2 (pt) Conjugados de dendrímero direcionado
BR0012138A (pt) Conjugado, composição que compreende conjugados, composição farmacêutica, utilização de um conjugado ou uma composição, processo para o tratamento profiládico e/ou terapêutico de distúrbios e processo para a preparação de um conjugado ou composição
BR112023018676A2 (pt) Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
BRPI0511296A (pt) sensibilização à outra terapia anticáncer e/ou melhora de um efeito colateral de outra terapia anticáncer por tratamento com um composto anticáncer ativado por gst
BRPI0410041A (pt) métodos para tratamento de dor de cabeça de sinusite
BRPI0406883A (pt) Composto, composição farmacêutica, método de tratar um distúrbio, e, uso de um composto
BR9815442A (pt) Liberação terapêutica dirigida de compostos de vitamina d
BRPI0512220A (pt) método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
BR0309167A (pt) Composto, processo para a produção de um composto, composição farmacêutica, uso do composto, método para o tratamento de um sujeito afetado por uma condição patológica ou doença e produto de combinação
BR0212008A (pt) Uso de um composto ou de um sal, solvato ou pró-medicamento deste, composição farmacêutica, composto ou um sal, solvato ou pró-medicamento deste, e, processo para a preparação deste
BR9713785A (pt) Composto, uso do mesmo, agente de diagnóstico, composição farmacêutica, e, processos para a preparação de um composto e para o tratamento da dor, de distúrbios gastrointestinais e de lesões na coluna vertebral.
BR0009647A (pt) Docetaxel em combinação com rhumab her2 para o tratamento de cânceres
BRPI0610093A2 (pt) composiÇço farmacÊutica, e, mÉtodo para prevenir ou tratar uma doenÇa associada com os depàsitos de amilàides de alfa-beta no cÉrebro de um paciente
BRPI0520032A2 (pt) moléculas para transportar um composto através da barreira hematoencefálica
RU2010137032A (ru) Конъюгаты паклитаксела с полимером и способы лечения рака
AR041061A1 (es) Uso de la eritropoyetina en pacientes con diabetes
BRPI0410316A (pt) composto, composição farmacêutica, uso dos compostos, e, método de tratamento de distúrbios mediados por vr1 e para o tratamento de distúrbios de dores
BR0207510A (pt) Conjugados de peg de hgf-nk4
BR0209128A (pt) Compostos, composições farmacêuticas, métodos para o tratamento de dores, métodos para a modulação de uma resposta farmacológica e usos de compostos
BRPI0414736A (pt) 5-aril-pirimidinas como agentes anticáncer

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06H Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette]

Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 38/18 (2006.01), A61K 47/60 (2017.01), A61P 2

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]